Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Aura Biosciences Inc (AURA)

Aura Biosciences Inc (AURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference GlobeNewswire - Tue Nov 26, 7:00AM CST

AURA : 8.20 (+1.11%)
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire - Tue Nov 12, 3:05PM CST

AURA : 8.20 (+1.11%)
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial GlobeNewswire - Thu Oct 17, 3:05PM CDT

AURA : 8.20 (+1.11%)
Author
3 Small-Cap Stocks Ready to Deliver Significant Growth MarketBeat - Thu Oct 10, 10:12AM CDT

Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.

TZOO : 19.97 (+1.78%)
AURA : 8.20 (+1.11%)
FBRT : 12.67 (+1.93%)
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights Business Wire - Wed Mar 15, 2023

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial...

AURA : 8.20 (+1.11%)
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration Business Wire - Thu Feb 16, 2023

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 8.20 (+1.11%)
Why Shares of Aura Biosciences Jumped This Week Motley Fool - Fri Feb 10, 2023

The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.

AURA : 8.20 (+1.11%)
Aura Biosciences to Participate in Upcoming Investor Conferences Business Wire - Thu Feb 9, 2023

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 8.20 (+1.11%)
Aura Biosciences Announces Pricing of Public Offering of Common Stock Business Wire - Wed Nov 30, 2022

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 8.20 (+1.11%)
Aura Biosciences Announces Proposed Public Offering of Common Stock Business Wire - Wed Nov 30, 2022

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 8.20 (+1.11%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot